<DOC>
	<DOCNO>NCT00614653</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose capecitabine , erlotinib hydrochloride , bevacizumab give combination radiation patient pancreatic cancer .</brief_summary>
	<brief_title>Bevacizumab , Erlotinib Capecitabine Advanced Pancreatic Cancer</brief_title>
	<detailed_description>The Study Drugs : Bevacizumab design prevent slow growth cancer cell block growth blood vessel . Capecitabine erlotinib hydrochloride design interfere growth cancer cell . Study Drug Dose Level : If find eligible take part study , begin receive capecitabine , erlotinib hydrochloride , bevacizumab . The dose receive base many participant enrol , safety data available . The first group enrol participant give low dos capecitabine , erlotinib hydrochloride , bevacizumab . If intolerable side effect occur , next group enrol high dose level . This process continue researcher find high dose capecitabine , erlotinib hydrochloride , bevacizumab give without intolerable side effect occur . The study doctor tell dose receive compare dose participant receive . Study Drug Administration : On Days 1 , 14 , 28 , receive bevacizumab needle vein . Your first infusion last 90 minute . If tolerate drug well , next infusion last 60 minute . If 60-minute infusion well tolerate , infusion last 30 minute . On day receive radiation , take capecitabine erlotinib hydrochloride mouth morning even food . Radiation : You receive radiation day Monday Friday , exclude holiday . This schedule continue 5 1/2 week 28 dos . Study Visits : Every week study , follow test procedure perform : - You physical exam . - Blood ( 2 teaspoon ) draw routine test . - You ask side effect may experience . - You repeat health questionnaire fill screening . Bevacizumab Surgery : If time study tumor remove surgically , surgery . A separate consent form would use . Because bevacizumab may slow heal wound , study participant may surgery within 10 week last bevacizumab infusion . Length Study : You remain study 5 1/2 week . You take off-study early disease get bad intolerable side effect occur . End-Of-Study Visit : Four ( 4 ) 6 week finish radiation , end-of-study visit follow test procedure perform : - You complete physical exam . - Blood ( 2 tablespoon ) urine collect routine test . - You chest x-rays CT scan abdomen . - You repeat health questionnaire . Additional Experimental Therapy : If appear benefit experimental therapy , study doctor may decide continue experimental therapy end-of-study visit . This would daily erlotinib hydrochloride , bevacizumab infusion every 2 week unless disease get bad intolerable side effect occur . You would study visit month , procedure weekly study visit ( except questionnaire ) . This investigational study . Capecitabine , bevacizumab , erlotinib hydrochloride FDA approve commercially available . The use capecitabine bevacizumab pancreatic cancer combination erlotinib hydrochloride investigational . At time , 3-drug combination use research . Up 30 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . ECOG performance status 0 1 . 2 . Patients must &gt; /= 18 year age . There upper age restriction . 3 . Cytologic histologic proof adenocarcinoma pancreas . Patients tumor originate part pancreas . Islet cell tumor eligible . Only patient non metastatic , unresectable disease eligible . Patients undergo resection underlie medical problem also eligible . Patients regional nodal disease eligible . 4 . All patient must stag physical exam , CXR , contrastenhanced helical thincut abdominal CT. Unresectability define CT criterion : ) evidence tumor extension celiac axis superior mesenteric ( SM ) artery , b ) evidence either CT angiogram occlusion SM vein SM/ portal vein confluence . If tumor meet definition find unresectable surgical exploration , tumor consider unresectable . 5 . Patients may receive prior chemotherapy prior radiation therapy upper abdomen . 6 . Bone marrow function : absolute neutrophil count ( ANC ) &gt; 1,500/ul . Platelets &gt; 100,000/ul . 7 . Hepatic function : Total bilirubin less 5mg/dL . If patient require endobiliary stent , bilirubin level must decline consecutive measurement indicate adequate biliary decompression ; alanine aminotransferase ( ALT ) &lt; /= 5 time upper limit normal . 8 . Renal function : BUN &lt; /= 30 mg % , creatinine &lt; /= 1.5 mg % creatinine clearance &gt; /= 30ml/min ( estimate calculate CockcroftGault equation ) . Note : In patient moderate renal impairment ( estimate creatinine clearance 3050 mL/min ) baseline , dose reduction 75 % capecitabine start dose recommend . 9 . Patients must sign informed consent indicate aware investigational nature study , aware participation voluntary . 1 . Prior abdominal radiotherapy . 2 . Imaging ( CT MRI ) endoscopic evidence direct duodenal invasion tumor . 3 . Prior therapy bevacizumab , cetuximab , gefitinib . Prior therapy erlotinib permit unless patient take erlotinib due treatment failure . 4 . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study . 5 . Prior severe infusion reaction ( bronchospasm , stridor , urticaria and/or hypotension ) monoclonal antibody . 6 . Prior unanticipated severe reaction fluoropyrimidine therapy know hypersensitivity 5fluorouracil . 7 . Proteinuria baseline clinically significant impairment renal function demonstrate urine dipstick proteinuria &gt; /= 2+ ( patient discover &gt; /= 2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate &lt; /= 1g protein 24 hour eligible ) . 8 . Prior history cancer within last five year except basal cell carcinoma skin carcinoma situ cervix . Patients previous malignancy without evidence disease 5 year allow enter trial . 9 . Pregnant lactating woman . Women childbearing potential either positive pregnancy test baseline . Women / men childbearing potential use reliable contraceptive method ( oral contraceptive , hormonal contraceptive , intrauterine device , diaphragm condom ) . ( Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) . Patients must agree continue contraception 30 day date last study drug administration . 10 . Serious , uncontrolled , concurrent infection ( ) require IV antibiotic nonmalignant medical illness uncontrolled whose control may jeopardize complication therapy . 11 . Uncontrolled hypertension [ blood pressure &gt; /=140/90 mmHg medication ] , New York Heart Association ( NYHA ) Class II great congestive heart failure , unstable symptomatic arrhythmia require medication ( subject chronic atrial arrhythmia , i.e. , atrial fibrillation paroxysmal supraventricular tachycardia eligible ) , significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) Class II great peripheral vascular disease , history stroke TIA within 6 month prior study enrollment , history hypertensive crisis hypertensive encephalopathy . 12 . History active angina myocardial infarction within 6 month . History significant ventricular arrhythmia require medication antiarrhythmic , history clinically significant conduction system abnormality . 13 . Psychiatric disorder render patient incapable comply requirement protocol . 14 . History evidence upon physical examination CNS disease ( e.g. , primary brain tumor , seizures control standard medical therapy , brain metastasis , history stroke ) 15 . Prior history pulmonary embolism deep venous thrombosis . 16 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study , define protocol ; fine needle aspiration core biopsy within 7 day prior Day 0 . 17 . Lack physical integrity upper gastrointestinal tract , malabsorption syndrome inability swallow . 18 . Known , exist uncontrolled coagulopathy , INR &gt; /= 1.5 . 19 . Patients Coumadin must change Lovenox least 1 week prior start capecitabine . Low dose ( 1 mg ) Coumadin allow . Intravenous lowmolecular weight heparin permit . 20 . Patients take Sorivudine Brivudine must drug 4 week prior start capecitabine . Patients take cimetidine must drug discontinue . Ranitidine drug another antiulcer class substitute cimetidine necessary . If patient currently receive allopurinol , must discuss PI see another agent may substitute . 21 . Current serious , nonhealing wound , ulcer , bone fracture . 22 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 0 . 23 . Patients organ allograft . 24 . Inability comply study and/or followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastinâ„¢</keyword>
	<keyword>Anti-VEGF monoclonal antibody</keyword>
	<keyword>rhuMAb-VEGF</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Erlotinib Hydrochloride</keyword>
	<keyword>Tarceva</keyword>
	<keyword>OSI-774</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Xeloda</keyword>
</DOC>